Hedera Dx develops blood-based liquid biopsy solutions and an AI-native platform that integrates advanced molecular diagnostics with clinical data to inform treatment decisions and support drug development. The company’s offering is designed for hospital in-house testing, aiming to make sophisticated molecular diagnostics locally affordable and easy to adopt. Its platform is already deployed across 11 European countries and the team comprises more than 20 professionals with expertise in genomics, oncology, bioinformatics, AI, and digital health. Hedera positions its real-world data capabilities as a way to generate patient-centric insights that can fuel next-generation oncology treatments. The company was founded in 2021 and is based in Lausanne. The Series A will support continued commercial expansion and further development of its real-world data infrastructure. Hedera Dx develops a blood-based liquid biopsy assay paired with end-to-end software (Hedera Prime) registered as an IVD medical device to enable hospital labs to run clinically actionable cancer tests in-house. The company combines a laboratory assay and streamlined software workflow for analytics, reporting and therapy options to overcome adoption hurdles in hospital laboratories. Hedera Dx plans to launch commercially in the autumn and to implement the first phase of a large oncology Real World Evidence (RWE) clinical testing program. The RWE program aims to create a landmark data asset on real-world usage of liquid biopsy and related cancer patient outcomes. Founded in 2021 by Tommi Lehtonen, Damien Lapray and Christian Meisel, the startup positions its solution to improve access to molecular profiling and therapy selection for cancer patients. The company has just raised new funding to advance these commercialization and clinical-data objectives.

Total raised

$32M

Funding rounds

2

Latest round

Series A

Latest activity

May 2025